TABLE 4.
Results of trials using combination fibrinolytics and glycoprotein IIb/IIIa inhibitors for facilitated percutaneous coronary intervention (PCI)
|
BRAVE (16) 2004 |
ADVANCE MI (15) 2005 |
|||
|---|---|---|---|---|
| Fac | Nonfac | Fac | Nonfac | |
| Angiographic outcomes | ||||
| TIMI-3 flow at initial angiography, % | 40* | 18* | 41* | 21* |
| TIMI-3 flow after PCI, % | 87 | 87 | N/R | N/R |
| TIMI blush score | Mean 2.4 | Mean 3.1 | 2–3: 30% | 2–3: 20% |
| LVEF (ventriculogram), % | 52 | 52 | N/R | N/R |
| Clinical outcomes, % | ||||
| Mortality† | 1.6 | 1.6 | 6.8* | 0.0* |
| Reinfarction | 0.8 | 0 | 1.4 | 2.7 |
| Reintervention | 0.8 | 0 | N/R | N/R |
| Congestive heart failure | N/R | N/R | 6.8 | 1.4 |
| MACE‡ | 6.4 | 4.7 | 12.2* | 2.7* |
| Safety outcomes, % | ||||
| Any stroke | 0.8 | 0 | N/R | N/R |
| Intracranial hemorrhage | 0.8 | 0 | N/R | N/R |
| Major bleeding episode | 5.6 | 1.6 | 14.9* | 8.1* |
| Transfusion requirement | 3.2 | 0.8 | N/R | N/R |
*
Significant difference P<0.05;
†
Mortality – BRAVE: 30-day; ADVANCE MI: 30-day;
‡
Major adverse cardiac events (MACE) – BRAVE: 6-month mortality or reinfarction or stroke; ADVANCE MI: 30-day death or congestive heart failure or cardiogenic shock. Fac Facilitated PCI; LVEF Left ventricular ejection fraction; N/R Not reported; Nonfac Nonfacilitated PCI; TIMI-3 Thrombolysis In Myocardial Infarction grade 3